Date(s) And Time(s):
Nov 3 2010 8:00AM - Nov 5 2010 5:00PM
Westin Ottawa Hotel
11 Colonel By Drive
Ottawa, ON K1N 9H4
Regulatory Affairs, Clinical Research, Clinical Safety/Pharmacovigilance, Quality Assurance/Quality Control, CMC
CALL FOR ABSTRACTS
for Presentations (details on page 3)
for Posters (details on page 2)
All abstracts are due by October 18, 2010
The biopharmaceutical community is experiencing a paradigm shift in drug development. Important global changes are occurring with respect to regulatory oversight to clinical trial design and execution. Several factors infl uencing these changes include: new scientifi c approaches; biomarkers and individualized medicine; healthcare reform and the interplay between safety pharmacovigilance and eff ectiveness research. In order to remain
competitive, Canada will need to foster innovation in these areas and facilitate market access to medicines.
World market dynamics have led to increased opportunities for both industry and regulators to share information while at the same time, introducing new challenges regarding privacy and/or confi dentiality and clinical trial competitiveness. The program will highlight information on improving effi ciency in the running of clinical trials; discussion of streamlining federal and provincial regulatory and formulary approvals; and advice on strategies to overcome obstacles.
Contact Joanne Wallace, Program Manager, Phone +1.215.442.6180
Fax +1.215.293.5931, email Joanne.Wallace@diahome.org
Attendees may visit the exhibits during the event and receptions.
Contact Jeff Korn, Exhibits Associate, Phone +1.215.442.6184
Fax +1.215.293.5924, email Jeff.Korn@diahome.org